Strengthening R&D functions through the conversion of the research institute into an R&D center
First written in FY2016. 20 of 27 entries say "Restated". Latest entry: 2026-06-09.
3 other companies' latest entry also says "Restated".
- 2026-06-09RestatedPresentation materials on financial results
「Maintained at the previous level」
The Company plans research and development expenses of ¥400 million for the 118th fiscal year, broadly maintaining the previous level of ¥403 million in the 117th fiscal year. - FY2026-H1RestatedAnnual report
「The Group’s total R&D expenditure for the interim consolidated accounting period was ¥201 million. There were no material changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥201 million were recorded, and the company reaffirmed that there were no material changes in its R&D activities. - FY2025Expansion into the integration of acquired products and support for their transferAnnual report
「During the consolidated fiscal year, as customer demand for environmentally friendly products increased, we focused on developing environmentally friendly products by reducing the volume of existing products, converting them to monomaterial products and biomass-based products, responding to various regulations and diversifying customer requirements, integrating products acquired through business transfers with our existing proprietary products, and providing transfer support in connection with the consolidation and integration of production facilities. R&D expenses for the consolidated fiscal year were ¥436 million.」
The focus of R&D expanded beyond environmental initiatives to the integration of acquired products and transfer support associated with the consolidation and integration of facilities. R&D expenses were ¥436 million. - FY2025-H1RestatedAnnual report
「The Group’s total R&D expenditure for the interim consolidated accounting period was ¥211 million. There were no material changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥211 million were recorded, and the company reaffirmed that there were no material changes in its R&D activities. - FY2024-Q2RestatedAnnual report
「The Group’s total R&D expenditure for the six months ended the second quarter was ¥200 million. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses of ¥200 million were recorded, and the company reaffirmed that there were no material changes in its R&D activities. - FY2024-Q1RestatedAnnual report
「The amount spent on research and development activities across the Group during the three-month period ended was ¥93 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended.」
R&D expenditure of ¥93 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2023RestatedAnnual report
「The group's basic R&D policy is for the sales departments of each of the Light Packaging Materials, Industrial Materials and Functional Materials segments to gather customer needs and, in cooperation with the R&D Center, develop new products that achieve high customer satisfaction and improve existing products. R&D expenditure for the fiscal year was ¥399 million.」
The company continues to have the sales departments and the R&D Center work together on new product development and improvements to existing products, and recorded R&D expenditure of ¥399 million. - FY2023-Q3RestatedAnnual report
「The group's R&D expenditure for the nine months ended 31 December was ¥288 million. There were no material changes in the status of the group's R&D activities during the nine months ended 31 December.」
R&D expenditure of ¥288 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「The group's R&D expenditure for the three months ended 30 June was ¥95 million. There were no material changes in the status of the group's R&D activities during the three months ended 30 June.」
R&D expenditure of ¥95 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2022RestatedAnnual report
「The group's basic R&D policy is for the sales departments of each of the Light Packaging Materials, Industrial Materials and Functional Materials segments to gather customer needs and, in cooperation with the R&D Center, develop new products that achieve high customer satisfaction and improve existing products.」
The company continues to have the sales departments and the R&D Center work together on new product development and improvements to existing products. R&D expenditure was ¥417 million, and no new facility-related milestone was indicated. - FY2022-Q3RestatedAnnual report
「The group's R&D expenditure for the nine months ended 31 December was ¥317 million. There were no material changes in the status of the group's R&D activities during the nine months ended 31 December.」
R&D expenditure of ¥317 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「The group's R&D expenditure for the six months ended 30 September was ¥213 million. There were no material changes in the status of the group's R&D activities during the six months ended 30 September.」
R&D expenditure of ¥213 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「The group's R&D expenditure for the three months ended 30 June was ¥108 million. There were no material changes in the status of the group's R&D activities during the three months ended 30 June.」
R&D expenditure was ¥108 million, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2021AdvancedAnnual report
「During the fiscal year, while COVID-19 was spreading worldwide, the company promptly developed antibacterial and antiviral products and launched new products as the Bipro series.」
The company reported concrete results from its R&D capabilities, including the R&D Center, developing antibacterial and antiviral products and bringing new products to market. R&D expenditure was ¥428 million. - FY2021-Q3RestatedAnnual report
「The group's R&D expenditure for the nine months ended 31 December was ¥313 million. There were no material changes in the status of the group's R&D activities during the nine months ended 31 December.」
R&D expenditure was ¥313 million, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「The group's R&D expenditure for the six months ended 30 September was ¥208 million. There were no material changes in the status of the group's R&D activities during the six months ended 30 September.」
R&D expenditure of ¥208 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「The group's R&D expenditure for the three months ended 30 June was ¥104 million. There were no material changes in the status of the group's R&D activities during the three months ended 30 June.」
R&D expenditure of ¥104 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2020RestatedAnnual report
「The group's basic R&D policy is for the sales departments of each of the Light Packaging Materials, Industrial Materials and Functional Materials segments to gather customer needs and, in cooperation with the R&D Center, develop new products that achieve high customer satisfaction and improve existing products.」
The company reaffirmed its R&D policy of having the sales departments and the R&D Center work together on new product development and improvements to existing products. R&D expenditure for the fiscal year was ¥442 million. - FY2020-Q3RestatedAnnual report
「The group's R&D expenditure for the nine months ended 31 December was ¥325 million. There were no material changes in the status of the group's R&D activities during the nine months ended 31 December.」
R&D expenditure was ¥325 million, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「The group's R&D expenditure for the six months ended 30 September was ¥217 million. There were no material changes in the status of the group's R&D activities during the six months ended 30 September.」
R&D expenditure of ¥217 million was recorded, and the company reaffirmed that there were no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「The group's R&D expenditure for the three months ended 30 June was ¥110 million. There were no material changes in the status of the group's R&D activities during the three months ended 30 June.」
R&D expenditure was ¥110 million, and the company states that there were no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「The group made capital investments of ¥557 million, primarily in testing equipment at the R&D Center.」
The company made capital investments of ¥557 million, primarily in testing equipment at the R&D Center, expanding its R&D facilities. - FY2019-Q3RestatedAnnual report
「The group's R&D expenditure for the nine months ended 31 December was ¥317 million. There were no material changes in the status of the group's R&D activities during the nine months ended 31 December.」
R&D expenditure for the nine months ended 31 December was ¥317 million, and the company states that there were no material changes in the status of its R&D activities. - FY2018AdvancedAnnual report
「During the fiscal year, the company installed additional testing equipment and expanded analytical instruments at the R&D Center, advancing the development environment. The development center's proximity to the Kakegawa Plant and Kakegawa Plant WEST has helped improve quality and accelerate development and mass production.」
Additional testing equipment was installed and analytical instruments expanded at the R&D Center, improving the development environment and accelerating development and mass production. - FY2017-Q3AdvancedAnnual report
「In terms of earnings, new depreciation expenses arose following the start of operations at the new Kakegawa Factory WEST and the R&D Center, the new hub for research and development activities. However, profits increased on higher sales of functional materials and the sustained low level of raw material costs.」
The R&D Center entered the operating phase, resulting in new depreciation expense. - FY2017-Q2AdvancedAnnual report
「In terms of earnings, depreciation expenses began during the period following the completion of the new Kakegawa Factory WEST and the R&D Center, the new hub for research and development activities. However, substantially higher profits were achieved through the sustained low level of raw material costs and improved profitability in functional materials.」
The R&D Center, the new base for research and development activities, was completed, and depreciation expense began during the period. This represents progress in developing facilities to strengthen R&D capabilities. - FY2016First statedAnnual report
「Finally, to strengthen and expand the functions of the research institute in Shizuoka, the institute will be relocated to the WEST building at the Kakegawa Plant during the current fiscal year and renamed the R&D Center. As the R&D Center will be adjacent to the Kakegawa Plant, the development and production divisions will work more closely together after the relocation to shorten development lead times and improve customer satisfaction.」
The company plans to relocate and rename the facility during the current fiscal year, strengthen coordination between the development and production divisions, and shorten development lead times.